X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Remedium and Exothera will demonstrate the industrialization potential of Remedium’s RMD 1101 (AAV2-FGF18). Remedium’s lead candidate is the only disease modifying gene therapy based on the clinically proven regenerative mechanism of FGF18 for the treatment of rheumatology.
Lead Product(s): RMD 1101
Therapeutic Area: Musculoskeletal Product Name: RMD 1101
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: Exothera
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 22, 2023
Details:
Through this partnership, Remedium aims to characterize the functionality of its lead candidate RMD 1101, in a range of in vitro, ex vivo, and in vivo efficacy models that will help to advance it toward IND.
Lead Product(s): RMD 1101
Therapeutic Area: Musculoskeletal Product Name: RMD 1101
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Tufts University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 15, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
